

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Relton *et al.*

Appl. No.: 10/587,714 (U.S. National

Phase of PCT/US05/02535)

Intl. Filing Date: January 28, 2005

For: **Treatment of Conditions
Involving Dopaminergic Neuronal
Degeneration Using Nogo
Receptor Antagonists**

Confirmation No.: 2306

Art Unit: 3722

Examiner: *To Be Assigned*

Atty. Docket: 2681.0450001/EJH/SAC

**Third Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form PTO/SB/08B is a document that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed on September 12, 2006 in connection with the above-captioned application.

A copy of document **NPL42** is submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language document **NPL42** cited on Form PTO/SB/08B:

Document **NPL42**, Lan-Xiang, W., *et al.*, "Nogo and Nogo Receptor," *Prog. Biochem. Biophys.* 29:834-836, Institute for Brain Disorders, Dalian Medical University and the Institute of Basic Medical Science, Academy of Military Medical Sciences (2002), is in a foreign language. An English language abstract of document NPL42 is attached at the end of the document on page 836.

Document NPL42 is a review article that discloses the research and development of Nogo and Nogo receptor. The reference describes the structural and functional characteristics of Nogo, as well as the distribution of Nogo in the body. The reference also describes ligand-binding studies of NgR and the distribution of NgR in the body. In addition, the reference describes an antibody to Nogo-A that can neutralize the inhibition of regeneration of neuronal axons by Nogo-A and improve neuronal axon regeneration after injury.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

Date: January 26, 2009

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
927964v1